Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 3/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506370 | 0.88 | MIF (0.34) | GSRMIFMPIMAT2APTGER1 | |
| SCHEMBL4510786 | 0.84 | MIF (0.34) | GSRMIFMPIMAT2AALDH1A2 | |
| SCHEMBL4523287 | 0.84 | MIF (0.37) | MIFBRD9ALDH1A2ALDH1A3 | |
| SCHEMBL4523638 | 0.80 | GSR (0.41) | GSRMAT2AMAPK14PTGER1BRD9 | |
| SCHEMBL4521476 | 0.77 | GSR (0.39) | GSRMAT2AMAPK14BRD9ALDH1A2 | |
| SCHEMBL4505934 | 0.77 | CNR1 (0.38) | GSRMAPK14DRD2HTR2AHTR2C | |
| SCHEMBL1991949 | 0.74 | TSHR (0.35) | MAT2ADPP4 | |
| SCHEMBL4510077 | 0.74 | PDE10A (0.34) | MIFMAT2A | |
| SCHEMBL4521828 | 0.73 | MAT2A (0.40) | GSRMAT2AMAPK14KCNH2 | |
| SCHEMBL4520411 | 0.73 | GRM1 (0.35) | MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | GSR 1941/4885MIF 3011/4885MPI 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.